Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

Learn about cost and Gleevec, financial and insurance assistance, ways to lower long-term costs, and more.

Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic ...

Painful crises in sickle cell disease or sickle cell anemia could potentially be treated using imatinib as a therapeutic option, a small study found.

The company said its study met expectations and showed that the 600 mg dose of IkT-001Pro was equivalent to standard-of-care 400 mg imatinib mesylate.

Imatib 100 Tablet 100mg - 10 Tablets Capsule (Imatinib mesylate (100mg)) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes . It is ...

Tenax is developing a novel formulation of imatinib mesylate, a kinase inhibitor that has received FDA’s orphan designation (March 2020) for the treatment of pulmonary arterial hypertension (PAH).

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec Tablets in the U.S. market approved by ...

Several years ago, a group of oncologists penned an editorial on drug prices, with Gleevec (imatinib mesylate), the groundbreaking tyrosine kinase inhibitor, as their illustration of egregious ...

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

As part of the company’s philosophy of putting patients' interests first, Sun Pharma announced the extension of its Imatinib Mesylate Savings Card Pro ...

Sun Pharma today, announced the launch of Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec for indications approved by the FDA) in the US market.